SCHEMBL1011707

SCHEMBL1011707

Fc1cc(Br)cc(Oc2ccc(C(F)(F)F)cn2)c1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.63
L3MBTL1 Q9Y468 3/20 0.51
MAPK1 P28482 1/20 0.51
MAPT P10636 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
LMNA P02545 1/20 0.47
KMT2A Q03164 1/20 0.46
TSHR P16473 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
RAB9A P51151 1/20 0.44
HPGD P15428 1/20 0.44
LIPE Q05469 6/20 0.43
BCHE P06276 1/20 0.43
SCN9A Q15858 1/20 0.41
POLB P06746 2/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1417238 0.91 THRB (0.69) THRBL3MBTL1MAPK1MAPTNPSR1
SCHEMBL4193757 0.90 THRB (0.53) THRBL3MBTL1MAPK1MAPTNPSR1
SCHEMBL31360386 0.84 THRB (0.61) THRBL3MBTL1MAPK1MAPTNPSR1
SCHEMBL31360509 0.84 THRB (0.61) THRBL3MBTL1MAPK1MAPTNPSR1
SCHEMBL1013808 0.84 THRB (0.61) THRBL3MBTL1MAPK1MAPTNPSR1
SCHEMBL24749780 0.83 THRB (0.52) THRBL3MBTL1MAPK1MAPTNPSR1
SCHEMBL31694814 0.83 THRB (0.52) THRBL3MBTL1MAPK1MAPTNPSR1
SCHEMBL1011792 0.81 THRB (0.57) THRBL3MBTL1MAPK1MAPTNPSR1
SCHEMBL1010964 0.81 THRB (0.57) THRBL3MBTL1MAPK1MAPTNPSR1
SCHEMBL1011398 0.81 THRB (0.72) THRBL3MBTL1MAPK1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101595102-B Diaryl ether urea compounds PFIZER PROD INC 2013-08-07 CN disclosed
US-8044052-B2 Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis PFIZER INC. (US) 2011-10-25 US disclosed
EP-2076508-B1 BIARYL ETHER UREA COMPOUNDS PFIZER PROD INC (US) 2011-01-05 EP disclosed
CN-101595102-A Diaryl ether urea compounds PFIZER PROD INC (US) 2009-12-02 CN disclosed
EP-2076508-A2 BIARYL ETHER UREA COMPOUNDS Pfizer Products Inc. (US) 2009-07-08 EP disclosed
US-20080261941-A1 Biaryl Ether Urea Compounds Jazz Pharmaceuticals Therapeutics, Inc. 2008-10-23 US disclosed
WO-2008047229-A2 BIARYL ETHER UREA COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261941-A1 Biaryl Ether Urea Compounds FAAH, FAAH2, LIPC THRB 2969/4885L3MBTL1 4652/4885MAPK1 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.